The treatment paradigm for HER2-positive breast cancer continues to evolve with a growing emphasis on anthracycline-sparing approaches and the refinement of initial strategies in both the early-stage and metastatic settings, according to Paolo Tarantino, MD.
“I do feel the future will have more and more anthracycline-sparing [regimens], acknowledging that there are few selected populations of patients that may still benefit from anthracyclines, such as those in whom HER2 positivity remains unclear, HER2-positive pregnant patients, and those with inflammatory breast cancer,” Tarantino said.
In an interview with OncLive®, Tarantino discussed the growing trend of avoiding anthracycline-containing regimens in the management of HER2-positive breast cancer; highlighted the enduring influence of the phase 3 CLEOPATRA trial…